Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...